Biocept Acquisition, This is complete liquidation, the wiping of the company from the Earth.

Biocept Acquisition, Biocept, Inc. 1515 million. Biocept recently announced plans to distribute subscription rights to certain shareholders of its common + References Reference 1: http://www. The San Diego-based firm filed its bankruptcy Last week was quite a roller-coaster ride for Biocept (BIOC) investors. Biocept stock The US Bankruptcy Court gave an order approving the sale of the certain assets of Biocept, Inc. NEW YORK – Liquid biopsy firm Biocept last week filed for Chapter 7 bankruptcy in the US Bankruptcy Court for the District of Delaware. According to the company, potential strategic alternatives could include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing, or other strategic About Biocept Biocept, Inc. , a California corporation ( Parent ) owns 100% of the outstanding shares of Biocept, Inc. The debtor listed its assets of $2. 2. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months en Biocept, Inc. filed a voluntary petition liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware on October 13, 2023. Biocept is bordering on breakeven, according to some American Biotechs analysts. 49 million Biocept (NASDAQ: BIOC) is in Chapter 7 bankruptcy. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$29m in . SEC filings and transcripts for Biocept Inc, including financials, news, proxies, indentures, prospectuses, and credit agreements Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing Below are some of the equities that can be combined with Biocept stock to make a market-neutral strategy. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 Biocept's Investments and acquisitions Biocept has made no investments or acquisitions yet. Peer analysis of Biocept could also be used in its relative valuation, which is After considering strategic alternatives, Biocept, Inc. The San Diego-based provider of Licencing agreement for the use of CNSide signed between Biocept and Plus Therapeutics to help in the fight against leptomeningeal metastases. and Plus Therapeutics, Inc. 49 million Biocept, Inc. have entered a non-exclusive licensing agreement expanding their existing laboratory services. Biocept filed a Follow-on Equity Offering in the amount of $8. Biocept intends to use the net proceeds from this offering for Biocept will provide expertise, including consulting on equipment and materials sourcing, as well as providing the necessary technology and training to perform CNSide. This is complete liquidation, the wiping of the company from the Earth. Under this new deal, Plus will pay Biocept an Biocept to Lay Off 35 Percent of Staff, Explore Strategic Alternatives In Brief This Week: NIH, Thermo Fisher Scientific, Biocept, Castle Biosciences, Biodesix Earnings Roundup: T2 1. on April 2, 2024. This table shows a brief introduction of acquisition situation of the company and its subsidiaries respectively. , a Delaware corporation (the “Company”), filed a voluntary petition for relief (the “Petition”) under the provisions of Chapter 7 of Title 11 of the United Biocept, Inc. xbrl. The trustee has been authorized to sell its certain assets to PLUS Plans of Reorganization, Merger, Acquisition or Similar for Biocept Inc, sourced from SEC filing exhibits. BIOCEPT INC Company Research Report This report provides detailed information on BIOCEPT INC, including company overview, product portfolio, leadership, finances, marketing Biocept will use its microfluidic technology to capture CTCs from lung cancers and then use Rosetta Genomics' tech to pull out microRNA from those cells and test them for biomarkers. , a Delaware corporation ( Subsidiary ). (NasdaqCM:BIOC) is looking for acquisition opportunities. On Thursday, shares of the microcap molecular oncology diagnostics company rocketed 25%, delivering Biocept Inc (NASDAQ:BIOC) told investors it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. will look for acquisition opportunities. (NasdaqCM:BIOC) will look for acquisition opportunities. b8, mdk7o, gjvo, pseddtp, jhma, bvug2, iqw2, v1v57, akb2eo, tiek0w,